Clinical Trial

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 13, 2024 (before its estimated December 10, 2024 completion). Its status may not reflect the trial's current state.
Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Trial Details
NCT Number NCT06686472
Lead Sponsor Telios Pharma, Inc.
Conditions Allergic Conjunctivitis
Enrollment 66 participants
Start Date 2024-10-03
Primary Completion 2024-12-10 (estimated)
Study Completion 2024-12-10 (estimated)
Updated on ClinicalTrials.gov 2024-11-13